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Summary.-Studies were conducted of the invivo therapeutic potential of compounds
which induce the differentiation of Friend leukaemia cells (FLC) in vitro. DBA2/J
mice were inoculated with Friend leukaemia cells grown in tissue culture and at
various times thereafter were treated with either N-methylacetamide, dimethyl-
acetamide, or tetramethylurea. While survival was only occasionally prolonged, in
every study these agents significantly inhibited leukaemia cell proliferation in the
spleen and to a lesser extent in the marrow. These agents had no effect on the
rate of proliferation of FLC growing subcutaneously nor on the proliferation of
myeloid leukaemia in RFMS mice. These studies indicate that the administration
of inducing agents to mice bearing Friend leukaemia can alter the proliferation
characteristics of the leukaemia cells and hence suggest that these agents may have
therapeutic potential.
MANY studies have demonstrated that
malignant cells possess the ability to
differentiate (Pierce and Wallace, 1971;
Prasad, 1972a; Prasad, GilmerandKumar,
1973; Goldstein, Burdman and Journey,
1964; Silagi and Bruce, 1970; De Cosse et
al., 1973) and that differentiation is
frequently associated with a decrease in,
or in a loss of, malignant potential
(Lehman et al., 1974; Prasad, 1972b;
Sinks, 1973; Ichikawa, 1969 and Lancet
editorial, 1975). These observations sug-
gest that it might be possible to treat
malignant disease by inducing the differ-
entiation of the tumour cells in vivo.
The Friend leukaemia system provides
an excellent model for testing this proposi-
tion. Friend leukaemia cells (FLC) can
be induced to differentiate in vitro by
any one of a number of cryoprotective
compounds (Preisler and Lyman, 1975;
Preisler, Christoff and Taylor, 1976).
This differentiation is associated with
decreased clonogenicity in agar (Preisler
et al., 1975) and perhaps decreased
malignancy as well (Friend et at., 1971).
The i.v. inoculation of FLC into mice
results in a malignant disease which is
characterized by leukaemic cell infiltra-
tion ofthe spleen, bone marrow, liver and
lymph nodes (Preisler et al., 1975). The
s.c. inoculation of the tissue culture
cells results in a tumour which is indis-
tinguishable from a myeloblastoma. Even-
tually dissemination occurs andthe animal
dies.
The ability of FLC to differentiate in
vitro upon exposure to defined chemical
agents, together with the ability of the
cells to produce a malignant disease when
inoculated into mice, suggested that it
would be possible to determine whether
the observations of induced differentia-
tion in vitro had any relevance for the
treatment of malignant disease in vivo.
We here report our initial studies of this
proposition. These studies clearly dem-
onstrate that the administration of induc-
ing agents in vivo can alter the prolifera-
tive characteristics ofa malignant disease.EFFECTS OF IN VIVO ADMINISTRATION
MATERIALS AND METHODS
Cells.-Friend leukaemia cells (line 745A)
were cultured as previously described (Preis-
ler and Giladi, 1975). On the 3rd day after
passage into fresh media the cells were
collected by centrifugation, washed once
with phosphate-buffered saline (PBS), re-
suspended in PBS at 5 X 106 cells/ml and
0-2 ml inoculated either s.c. or i.v.
into 8-12-week-old male DBA2/J mice.
Except where indicated there were 10 mice
in each experimental group.
Animals.-The mice were housed in
cages containing 10 animals and allowed
food and water ad lib. As indicated above,
they were inoculated i.p. or s.c. with either
PBS or the appropriate inducing agent and
weighed twice weekly. Dead animals were
weighed and autopsied; the intra-abdominal
and intra-thoracic organs were inspected,
and then the liver, spleen and kidneys
removed and weighed.
Inducing agents.-These agents were dis-
solved in PBS to make the appropriate
concentrations as indicated in the text
below. The abbreviations used in the text
are: N-methyl-acetamide (NMA), dimethyl-
acetamide (DMA), and tetramethylurea
(TMU). The inducing agents and the PBS
were kept in a refrigerator and glass syringes
were used throughout an experiment.
Clonogenicity assay.-In vitro culture of
bone marrow and spleen cell suspensions
in plasma clots (Stephenson et at., 1971) was
used as a functional test for the presence
of leukaemic cells. In our hands neither
normal spleens nor normal bone marrow
cells form colonies in plasma clots in the
absence of added colony-stimulating factor
or erythropoietin. Furthermore, we have
been unable to demonstrate CSF production
by FLC (unpublished). Finally, the morpho-
logical appearance of the colonies produced
by FLC in plasma clots is distinctly different
from those formed by either normal granulo-
cytic or erythroid colony-forming units.
Hence we used the number of colonies pro-
duced by the bone marrow or spleen cells
of mice bearing FLC as an indication of
the relative number of leukaemic cells
present.
Appropriate dilutions of both spleen
and bone marrow cell suspensions were made
and used to seed plasma clots (spleen cells
at 105/ml final concentration and 2 x 104/ml
of bone marrow cells). The clots were
cultured in microtitre wells with 0-1 ml/well.
The cultures were incubated at 3700 in
a humidified atmosphere consisting of 95%
room air and 5% CO2. The number of
colonies present was determined 7 days after
seeding. A group of 20 or more cells was
considered to be a colony. Four to 8 culture
wells were counted for each point. Each
experiment included a bone marrow and
spleen cell suspension from a normal mouse
to rule out the possibility of spontaneous
colony formation by the residual normal
cells present in the leukaemic mice.
Studies of the kinetics of the effects of
NMA on FLC growing in vivo.-In these
two studies mice were inoculated with FLC
i.v. and 7 days later (t = 7) 7 mice were
sacrificed and the following studies carried
out:
1. VWhite blood cell count, differential,
haematocrit, reticulocyte count on
a blood specimen obtained from each
mouse.
2. The spleen, liver, and kidneys of each
mouse were inspected and weighed.
3. Bone marrow and spleens were studied
cytologically and functionally. Mar-
row and spleen cell suspensions from
each mouse wereprepared aspreviously
described (Preisler and Henderson,
1971). The 7 individual spleen cell
suspensions and the 7 individual bone
marrow cell suspensions were pooled
to provide 3 separate spleen cell and
3 separate bone marrow cell suspen-
sions in the following manner: the
respective spleen cell suspensions and
the marrow cell suspensions of the
mice with the 2 largest spleens were
combined, as were the spleen and
marrow suspensions of the mice with
the 2 smallest spleens. The spleen
and marrow suspensions of the 3 mice
with the spleens of intermediary size
were pooled. The cell suspensions
were counted and slides were made
for differential counting. In experi-
ment 2 the proportion of leukaemic
cells present was also assayed by
determining the clonogenicity in
plasma clots.
On Day 7 (t = 7) additional groups of
leukaemic mice were randomly assigned to
receive daily i.p. injections of either PBS
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(0-01 ml/g body wt.) or NMA (001 ml of
a 10% solution/g of wt.). In experiment 1,
7 mice received PBS and 14 mice received
NMA injections for 1, 2, 3, or 4 days re-
spectively. Seven mice from each group
were sacrificed 24 h after their last injection
and studied as described above for mice
at t = 7. The remaining mice which re-
ceived 1, 2, 3, or 4 days of NMA therapy
were not sacrificed but rather were followed
until death, at which time they were
autopsied. As a control for these latter
studies, 10 mice received a daily inoculation
of PBS for 4 days starting on t = 7 and
were then followed until death. Experiment
2 was similar to experiment 1 except for
the following: (1) the mice received daily
NMA injections for 1, 4, 6, or 7 days, and
(2) the spleen and bone marrow cell suspen-
sions were cultured in the plasma clot
system. In experiment 2 mice began to
die on Day 6 (t= 13). Therefore on Days
6 and 7 only the following studies were
done: the spleens were weighed (from mice
who were sacrificed as well as from those
mice which spontaneously died of their
disease), and the survival data were deter-
mined. The other studies were not done
because it was felt that the spontaneous
death of diseased mice would spuriously
skew the data.
Differential counting of the cells present
in the bone marrow and spleen.-Slides were
made of both marrow and spleen cell suspen-
sions using a cytocentrifuge. The slides
were benzidine- and Wright-Giemsa-stained.
A single observer in a single-blind fashion
determined the proportion of FLC (large
basophilic cells), nucleated erythroid cells,
myeloblasts and promyelocytes, segmented
neutrophils, metamyelocytes and lympho-
cytes.
Effects of NMA on normal mice and
on murine myeloid leukaemia.-Three to
4 month old DBA2/J mice were inoculated
daily for 7 days with either PBS (0 01 ml/g
body wt.) or NMA (0 01 ml of a 10% solu-
tion/g body wt.). Mice were sacrificed and
the same studies as were described for
"kinetics of the effects of NMA " were
carried out. Identical studies employing
RFMS mice were carried out with the daily
injection for 12 days.
Twenty-six RF mice were inoculated
with 106 spleen cells from a mouse bearing
myeloid leukaemia. Six days later 8 mice
were sacrificed and the remaining 18 mice
divided into two groups: 9 to receive daily
PBS injections and the other 9 to receive
daily NMA injection as described above.
The experiment was terminated on the
day the first mouse died. The animals were
studied as described above.
A technical difference from those studies
on mice bearing Friend leukaemia was
that the number of marrow cells/femur and
the differential counts of the spleens and
bone marrows were carried out on each
mouse rather than on pooled specimens as
previously described.
RESULTS
A. Effects of NMA on normal mice
Normal DBA2/J and RFMS mice
were injected with NMA for 7 and 12
days respectively. Table I gives the
results. NMA administration resulted in
a decrease in splenic weight and an
increase in the weights ofliver and kidney.
The number of cells/femur also declined
and there was suggestive evidence for
a decline in splenic erythropoiesis, while
the proportion of lymphocytes increased.
There were no other consistent NMA-
induced alterations. All animals appear-
ed to be healthy at the time of sacrifice
and the gross morphology of all organs
appeared normal.
B. Friend leukaemia studies
Clinical characteristics of Friend dis-
ease.-Palpable splenomegaly was present
in the majority of mice within 10-14 days
after i.v. inoculation of FLC. Shortly
thereafter the animals appeared ill
(hunched up, roughened fur) and many
became paraplegic. The mice died several
days later. While the median time to
death varied somewhat between experi-
ments, within an individual experiment
it was usually fairly uniform (Fig. 4).
Effects of daily drug administration to
mice with Friend leukaemia.-In 10 separ-
ate experiments daily, i.p. injection of
NMA (0-01 ml/g body wt. of a 10%
solution) was begun at either 4 or 7 days
after leukaemic cell inoculation and con-
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TABLE I.-Effect of NMA on Normal Mice
Body xwt
(g)
DBA2/J-PBS 25±0.5*
NMA 25±0- 8
RFMS PBS
NMA
Hct.
(0)
46±0 4
49±1
P<0 025
29±0- 8 46± 1
31±0-6 49±0-8
0 l>P>0-05
Spleen wt
(mg)
80±7
59±6
0- 1>P>0-05
Liver wt
(mg)
1250± 45
1378±44
Spleen cell
differential
M%t
RBC Lymphs.
13±2 73±2
11±1 83±2
P<0 005
154±12 1443±42 19±3 64±3
100±4 1941±63 8± 1 86±2
P<0*01 P<0-01 P<0-02 P<0-01
Total cell
count x 10-6/
femur
14-8±0-9
12-3±0-8
0-1>P>0-05
14-3±0-5
8-2±0-8
P<0.01
* Alean ± s.e.
t % of nucleated erythroid precursors and lymphocytes.
Eighteen 4-month-old DBA2/J mice were divided into two groups. Nine mice received PBS (0-01 ml/gm
wt) and 9 mice received NMA (001 ml of a 10% solution/g) i.p. for 7 (lays an(d were then sacrificed. The
RFMS were treated the same except that PBS and NMA were administered for 12 days.
tinued until death. Control mice received
PBS. In an occasional experiment sur-
vival appeared to be prolonged by the
administration of NMA. At the time
of death, in every experiment the spleens
of the NMA-treated mice were always
smaller than those of the control mice.
Studies employing the same total daily
dose of NMA but administered in divided
doses (twice a day) yielded identical
results (no consistent prolongation of
survival but the spleens of treated mice
were always significantly smaller than
those of the controls; Fig. 1). The
twice daily injection of DMA (0.005 ml/g
body wt. of a 10% solution) or TMU
(0.05 ml/g of a 25% solution) produced
the same effects as NMA (Fig. 1).
Since the major drug effect appeared
to be on the spleen and since the NMA
was being administered by the i.p. route
it seemed possible that the effects which
we observed might be due to a direct
effect on the spleen. To rule this out,
experiments which were identical to
those described in the preceding para-
graph but in which the NMA was injected
s.c. were done (6 separate experiments).
In each experiment the results were
identical to those in which the i.p. route
of injection was used (only occasional
prolongation of survival, but always
inhibitory effects on leukaemic cell pro-
liferation in the spleen).
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FiG. 1. Mice were inoculated i.v. with FLC
at t = 0. Beginning on Day 4, the mice were
inoculated i.p. with either saline (0 005 ml/g
BID), NMA (0 005 ml of 10 % solution/g
BID), TMU(0- 05 ml BID ofa250%solution)
or NMA-TMU (0 005 ml NMA in AM and
0 05 ml TMU in PM).
Kinetics ofthe effects ofNMA. Within
one day of administration, NMA had
demonstrable effects on spleen weight
and on the proportion of leukaemic cells
in the spleen and bone marrow (Fig. 2a).
By Day 4 (t II) the spleens of the
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FIG. 2.-Kinetics of NMA effects. (a) Mean of splenic weights of serially sacrificed mice. (b)
Effect of NMA on the proportion of FLC in the spleen. (c) Effect of NMA on the proportion of
femoral FLC.
PBS mice were 21 to 31 times as large
as those of the treated mice. These
differences persisted for at least 7 days.
It is of interest that during this interval
there was virtually no change in the
spleen size ofthe treated mice. Similarly,
the proportion of leukaemic cells in the
spleens of the treated mice remained
quite low during these 4 days while that
of the controls progressively increased
(Fig. 2b). By contrast, the proportion
of leukaemic cells in the femoral marrow
of both NMA-treated and control mice
increased, though the rate of increase in
the former was less than in the latter
(Fig. 2c). The plasma clot clonogenicity
studies agree with the histological assess-
ment as to the greater proportion of
leukaemic cells in the spleens and femurs
of PBS-treated mice. At t = 7, the
spleen and femurs of the leukaemic mice
produced 2 colonies/104 cells and 14
colonies/103 cells respectively. After 1
day of PBS or NMA administration the
spleens produced 5 and 4 colonies/104
cells respectively and after 4 days of
PBS or NMA administration the number
of colonies produced by 104 leukaemic
spleen cells was 227 for the PBS- and 63
for the NMA-treated mice. After 4 days
of treatment the femurs of PBS-treated
mice produced more than 150 colonies/103
cells (too many colonies to count) while
that of the NMA-treated mice produced
65 colonies/103 cells. There were several
other consistent differences between the
NMA treated mice and the control mice.
The number of bone marrow cells present
638
I
t 300- I'
Z 200'
100-
C
00-
i 40
!d
20
0
I~ |l
Ant
.w. e
a _1EFFECTS OF IN VIVO ADMINISTRATION
EXP.1
A
A
A EXP.1
A EXP.2 i
£
z u
a
EXP.2
B
EXP.1
(b)
EXP. 2
D
IMA
(c)
FIG. 3.-Kinetics of NMA effects. (a) Comparison of the number of femoral marrow cells in PB3S
and NMA treated mice. The % difference was calculated using the following equation:
Average no. femoral cells from average no. femoral cells from
NMA treated mice PBS treated mice 1
Average no. femoral cells from PBS treated mice x
(b) Effect of NMA on the proportion of splenic nucleated erythroid cells in mice with Friend
leukaemia. (c) Effect of NMA in the proportion of splenic lymphocytes in mice with Friend
leukaemia.
in the femurs of the NMA treated mice
was greater than that of the controls
(Fig. 3a). This effect was so apparent
that an observer had little difficulty
identifying the femur of an NMA-treated
mouse on the basis of its gross ap-
pearance. With the exception of the
proportion of leukaemic marrow cells,
there were no other detectable differences
between the bone marrows of NMA-
and PBS-treated mice. On the other
hand, the proportion of erythroid pre-
cursors in the spleens of NMA-treated
mice declined between Days 1-4 while
it increased in the spleens of the control
mice (Fig. 3b). The proportion of lym-
phocytes in the NMA-treated mice re-
mained fairly constant while that of the
PBS controls declined (Fig. 3c). In the
PBS-treated mice the data given in
Fig. 3b and c probably represent continued
proliferation ofFLC resulting in a relative
decrease in the number ofsplenic lympho-
cytes and an increase in splenic erythroid
precursors either as a reaction to the
presence of FLC or as the progeny of
42
theFLCthemselves. IntheNMA-treated
mice, inhibition of FLC proliferation
prevents the relative decline in lympho-
cytes and the increase in erythroid
precursors. There were no consistent
differences in the proportion of either
metamyelocytes or mature granulocytes,
whilst there was some suggestion of a
slight rise in the proportion ofmyeloblasts
and promyelocytes, in the spleens of
NMA-treated mice.
There were no consistent differences
in the peripheral white-blood cell counts,
leucocyte differentials, haematocrits, or
reticulocyte counts between the NMA-
treated mice and the controls.
Figure 4 shows the survival data of
the mice in which NMA therapy was
administered for 1 or more days and
then discontinued and the mice permitted
to die of their disease. In both experi-
ments there is a suggestion that the
NMA-treated mice survived slightlylonger
than the PBS controls, particularly for
the mice which received NMA for 4 days.
Table II gives the splenic weights at
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FIG. 4.-Effect of NMA on the survival of mice with Friend leukaemia. Mice were treated with
NMA for the indicated periods of time and then permitted to die of their disease. Arrow indicates
start of treatment.
TABLE II.-Effect of a Short Course of NMA Administration on Spleen Wt. at the Timte
ofDeath
Exp. 1
Duration of ,_ A_
treatment PBS NMA
1 148±49*
2 149±35
3 - 221±37
4 224±38 219±66t
(165±45)
6 -
7 -_
Exp. 2
PBS NMA
- 317±63
191±434
- 168±27
407±32 117±16
* Mean spleen wt. (mg) ± s.e.
t One mouse in this group survived for 47 days (median for the other 6 mice was 16-5 days). The
spleen of this mouse weighed 540 mg. The figures in parenthesis give the mean and standard error if the
weight of this mouse's spleen is not included in the calculation.
t Average of 6 spleens, one mouse alive at 50 days.
DBA2/J mice bearing Friend leukaemia received daily treatment with either PBS or NMA for the
indicated periods of time and then were followed until death (not sacrificed). The survival curves for
these mice are given in Fig. 4.
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the time of death of the mice in these
experiments. Several observations are
worthy of consideration. Even though
treatment with NMA had been stopped,
the splenic size of the NMA-treated mice
at the time of death was smaller than
that of the control mice. Comparison
of the data presented in Table II with
that presented in Fig. 2a reveals that in
the majority of cases there was no
significant difference in the spleen sizes
between mice which were treated with
NMA for a finite period of time and then
were sacrificed, and mice which received
the same NMA treatment but which
were not sacrificed, but were permitted
to die as a result of their disease. Since
their spleens (the major site of leukaemic
proliferation) were smaller, at the time of
death the total body tumour load of mice
which had received NMA for 1 or more
days was less than that of control mice.
Effect of NMA on the growth of s.c.
tumour8s.-In a similar experiment, 40
mice were inoculated s.c. with 106FLC.
On Day 4, prior to the appearance of
the tumours, the mice were divided into
4 groups of 10 mice. One group received
daily i.p. inoculations of PBS while the
other three received either NMA, TMU,
or NMA/TMU. Figure 5 illustrates the
rate of growth of tumours. Eight days
after tumour cell inoculation, and 4 days
after initiation of drug administration,
the tumours in the PBS- and NMA/TMU-
treated groups were slightly larger than
those of the other 2 groups. Over the
next 10 days the rate of increase in
tumour size for each of the groups
was identical, indicating that neither
NMA nor TMU administration inhibited
tumour growth. While the survival of
the treated mice was less than the con-
trols, the spleen sizes of the TMU- and
NMA-treated mice were less than that
of the control mice (control 221 ± 61 mg,
NMA 31 ± 9 mg, TMU 60 ± 19 mg, and
NMA/TMU 124 ± 25 mg) indicating at
the time of death a drug effect on leuk-
aemic cells growing in the spleen despite
a lack of effect on tumours growing s.c.
E
E
N
DAY5
FIG. 5.-EffectofNMA,TMU, orNMA+TMU
on the growth of FLC s.c. Doses were the
same as those used in Fig. 1. The numbers
aboveeach indicate thenumberofsurviving
mice. The two greatest diameters of each
tumour were measured and multiplied to
arrive at tumour size. Within each group
the size of the tumours were averaged.
There were 10 mice in each group. Arrow
indicates start of treatment.
After Day 18 the slope of the increase in
tumour size of the treated mice became
less than that of the controls. This
occurred at a time at which the treated
mice appeared to be dying of drug
toxicity, and may have been secondary
to the generally toxic state of the mice.
These observations are similar to
other observations made in the course
of these studies. In 3 separate studies
neither the direct injection of DMSO
or DMA (3 x /day for 10days) nor their
topical application had an inhibitory
effect on the rate of increase in tumour
size. In addition, occasional mice who
had received i.v. inoculations of FLC,
developed lymph node enlargement, tu-
mour growth at the site of FLC inocula-
tion or peri-rectal masses. We have
found that tumours growing in these
sites continue to enlarge in NMA-treated
mice despite the fact that the splenic
disease is arrested.
Other effects of NMA.-Occasionally
the livers of the PBS control mice were
mottled in appearance. This was much
more frequent in NMA-treated mice and
in these latter mice it was not uncommon
to detect obvious fatty degeneration.
641H. D. PREISLER, S. BJORNSSON, M. MORI AND G. H. LYMAN
~~~~~~~t.;
8 a>3
0
00 2 (;
X o
C) aq * -H -Hd-H
o24 , 0!
- Iz-
14)
Zs -
-0,0, Z.t -
'4) -, .-4 -5
4.'.)
prs 0
.ez
(Z
p Q (1)
C4) -<
;Z-. Itz
.i -4
a)
14) C)
9. 0
k.Q (1)
a) 's $a,
m
9
Dbt '- c
+g +-+
m
mo Ica aq 0
_0
-H H
eD2e
I t
00
o -H- o
Ki a) > +++~aq a
C H
H 00 m
-2
oH 3_ o.
*
642
L-1
rsEFFECTS OF IN 17IVO ADMINISTRATION
Preliminary pathological studies of these
livers are consistent with hepatic necrosis.
The NMA-treated mice also lost more
weight during the course of their disease
than did the control mice (350 vs. 25%
of body wt.). In addition, NMA ap-
peared to have some neurological side
effects since treated mice often shook
when they were picked up. NMA did
not alter the gross morphology of the
kidneys or kidney wt. NMA appeared
to be more toxic to mice bearing Friend
leukaemia than to normal mice.
C. Effects of NMA on murine myeloid
leukaemia
The effects ofNMA on murine myeloid
leukaemia differed from its effects on
Friend leukaemia (Table III). NMA ad-
ministered for 5 days failed to prevent
the progressive splenomegaly which cha-
racterizes this disease. NMA also failed
to significantly alter the cellular composi-
tion of either the bone marrow or spleen,
although there was a suggestion of a
mild inhibitory effect on myeloblast pro-
liferation.
DISCUSSION
Iv. inoculation into mice of Friend
leukaemia cell line 745A grown in tissue
culture results in a malignant disease
in which the spleen and bone marrow
are the major sites of leukaemic cell
proliferation. Occasionally, and most fre-
quently in the mice which survive the
longest, there is leukaemic cell prolifera-
tion in lymph nodes, and in rare instances
there are subcutaneous tumours at the
site ofleukaemic cell inoculation.
The administration of NMA, DMA, or
TMU results in major alterations in the
proliferative characteristics of the disease.
In these treated mice the splenic disease
was arrested and there also appeared to
be a retardation in the proliferation of
the leukaemic cells in the bone marrow.
The significance of this latter effect is
unclear since it appears that the total
number of marrow cells was greater
in the treated mice and if one multiplies
the percentage of leukaemic marrow cells
by the total number'of marrow cells the
difference between the NMA- and PBS-
treated mice diminishes. These effects
appear to be similar to the effects of
NMA on normal haematopoietic elements.
When administered to normal mice, NMA
produced a decrease both in splenic wt.
and in the number of femoral marrow
cells. It would appear that the apparent
increase in splenic lymphocytes is relative
rather than absolute and results from a
decrease in the other haemotopoietic
elements.
The mechanism of action of these
compounds is unclear since we found no
evidence of induction of differentiation
of the Friend leukaemia cells in vivo.
Rather, the effects appeared to be due to
an inhibition of Friend leukaemia cell
proliferation perhaps similar to the ef-
fects of NMA on the haematopoietic
elements of normal mice. These effects
could be the result of a direct drug
effect on the proliferating cells themselves
(possibly due to a decrease in intra-
cellular nucleotide pools (Preisler and
Rustum, 1975)) or, alternatively, the
drug could influence the microenviron-
ment in which the cells are proliferating.
Changes in the microenvironment could
then affect cell proliferation. Microen-
vironmental influence on leukaemic cell
proliferation have been previously re-
ported (Metcalf and Moore, 1970). In
favour of this hypothesis is the lack of
effect on NMA on Friend leukaemia cells
proliferating s.c.
Since NMA affected normal DBA2/J
mice and RFMS mice in an identical
fashion, the difference between the effects
of NMA on Friend leukaemia cells and
on murine myeloid leukaemia must be a
result of the differences between the
leukaemia cells, and not due to differences
in the effects of NMA on these two
strains of mice. In favour of this possi-
bility is the lack of NMA effect on Friend
leukaemia cells proliferating s.c. since
the tumours produced at this site are
devoid of erythroid elements and are
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indistinguishable from myeloblastomata
(Preisler et al., 1975) whereas Friend
leukaemia cells proliferating in the spleen
produce erythroid elements, as previously
described.
The observations that NMA adminis-
tration resulted in an increase in the
haematocrits of normal mice and mice
bearing myeloid leukaemia deserves fur-
ther comment. This apparent increase
cannot be ascribed to dehydration since
there was no difference in the weights
of the animals. Furthermore in pre-
liminary studies we have observed that
the administration of DMSO to post-
hypobaric polycythaemic mice resulted
in an increase in 59Fe incorporation into
red cells, an effect which, appeared to be
blocked by anti-erythropoietin antibody
(unpublished). These effects were not
observed in mice bearing Friend leuk-
aemia, perhaps because the disease itself
appears to adversely affect normal ery-
thropoiesis andresult in anaemia. Never-
theless, the apparent increase in cir-
culating red cell mass appears to be a
paradox in view of the apparent NMA-
induced decrease in haematopoietic ele-
ments in both spleen and bone marrow
and in the absence of a reticulocytosis.
While these observations, along with
those of inhibition of Friend leukaemia
with little effect on myeloid leukaemia
suggest a relationship between NMA
effect and erythropoiesis, the nature of
this relationship awaits further defini-
tion.
Despite altering the nature of the
disease and producing a markedreduction
in leukaemic cell body burden, these
agents did not consistently prolong sur-
vival of leukaemic mice. Two possible
explanations suggest themselves. Per-
haps there was no prolongation of sur-
vival because the tumour cells were
proliferating in a site " protected " from
the effects of NMA. For example, pro-
liferation of leukaemic cells in the spinal
cord may have been unaffected by NMA
because of " microenvironmental" re-
sistance. The mouse would then become
paraplegic and die of thirst and starva-
tion.
An alternate explanation relates to
the hepatic toxicity of NMA. The livers
of treated mice (bearing Friend leuk-
aemia) were frequently enlarged and
yellow. Preliminary pathology studies
are consistent with hepatic necrosis. It
is possible that the beneficial affects of
the reduction in tumour load were
counterbalanced bythe hepatotoxic effects
of NMA. Perhaps the apparent bene-
ficial effects of 4 days of therapy reflects
a fortuitous balance between the hepato-
toxic and anti-Friend leukaemia effects of
NMA.
In any event, agents which induce
the differentiation of Friend leukaemia
cells in vitro can also alter the pro-
liferation of these cells in vivo. While
the mechanism of action and the optimal
mode of administration are not known,
these agents may represent a new class
of antileukaemic compounds.
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